CYP3A4 and adrenal cortex carcinoma: Moreover, mitotane, the drug used for treatment of all our ACC patients, is known to stimulate CYP3A4 expression, potentially leading to reduced 1α,25(OH)2D3 bioavailability and reduced VDR expression in adrenals [10].